Surrozen, Inc.
NASDAQ: SRZN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Nasdaq Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig Parker
- Employees
- 42
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $185.1M
- Website
- https://www.surrozen.com
Loading SRZN…
Loading profile data…Frequently asked questions about SRZN
What does Surrozen, Inc. (SRZN) do?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central ne...
Where does SRZN trade?
Surrozen, Inc. (SRZN) trades on the Nasdaq Capital Market.
What sector is SRZN in?
Surrozen, Inc. (SRZN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Surrozen, Inc.?
Craig Parker is the chief executive officer of Surrozen, Inc. (SRZN).
Where is Surrozen, Inc. headquartered?
Surrozen, Inc. is headquartered in United States.
Does SRZN pay a dividend?
Surrozen, Inc. (SRZN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SRZN go public?
Surrozen, Inc. (SRZN) completed its initial public offering in 2021.